Upadacitinib-Methotrexate Combination Therapy for Refractory Atopic Dermatitis: A Case Series of a Novel Therapeutic Approach

Clicks: 20
ID: 329088
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #119 of 245 articles by views in clinical and experimental dermatology

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 245 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
We report a single-centre case series of four adults with severe, treatment-refractory atopic dermatitis treated with combined upadacitinib and methotrexate. All patients had failed multiple prior systemic therapies, and while upadacitinib induced initial improvement, addition of methotrexate led to further disease control. Following combination therapy, all achieved EASI-75 or greater, including three patients attaining EASI-90/100 with marked improvements in quality of life.
Reference Key
openalex_W7213548622 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Aoife Gaffney, Brian Kirby, Ali Alsharqi
Are you one of these authors? Claim your profile
Journal clinical and experimental dermatology
Year 2026
DOI
10.1093/ced/llag405
URL
https://doi.org/10.1093/ced/llag405
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.